Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Updated Results from a Phase Ⅱ Clinical Trial：Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia

Chuting Yang, Rui Huang, Danian Nie, Yiqing Li, Yuming Zhang, Honghua He, Chaoyang Song, Sanfang Tu, Yaling Zheng, Xuan Zhou, Jie Chen, Hui Zeng, Yuhua Li

Blood (2024) 144 (Supplement 1): 1050.

https://doi.org/10.1182/blood-2024-201586

Published: 2024

Journal Articles

Demographic and Clinical Data in 118 Acquired Hemophilia a: Results from a Single Center Study

Hu Yingying, Xuan Zhou, Shuhua Li, Jing Sun, Jieyu Ye, Qifa Liu, Houmei Feng

Blood (2024) 144 (Supplement 1): 3979.

https://doi.org/10.1182/blood-2024-206976

Published: 2024

Journal Articles

Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

Jieping Lin, Chenhao Ding, Zicong Huang, Cai Zihong, Jia Li, Zhixiang Wang, Xiaofang Li, Xuan Zhou, Bailin He, Wenhao Zhong, Li Xuan, Qifa Liu, Yang Xu, Hongsheng Zhou

Blood (2024) 144 (Supplement 1): 839.

https://doi.org/10.1182/blood-2024-200513

Published: 2024

Journal Articles

Analysis of the Impact of TKI Dose Adjustment Under the Guidance of Blood Concentration Monitoring on the Efficacy, Safety and Quality of Life in Patients with CML

Zherou He, Qing Zhang, Xuan Zhou, Qiang Wang, Xiaoli Liu, Na Xu

Blood (2024) 144 (Supplement 1): 1773.

https://doi.org/10.1182/blood-2024-207302

Published: 2024

Journal Articles

The Efficacy and Safety of Selinexor Plus Ruxolitinib Regimen in Ruxolitinib-Resistant Myelofibrosis: A Retrospective Study

Ziyu Wen, Xuan Zhou, Bingyu Lin, Xiaoli Liu, Qiang Wang, Na Xu

Blood (2024) 144 (Supplement 1): 1803.

https://doi.org/10.1182/blood-2024-205725

Published: 2024

Journal Articles

Clinical Characteristics and Risk Factors of Chronic Kidney Disease Among Patients with Myeloproliferative Neoplasms

Zicheng Gao, Xuan Zhou, Qiang Wang, Dan Xu, Xiaoli Liu, Na Xu, Qifa Liu

Blood (2024) 144 (Supplement 1): 6643.

https://doi.org/10.1182/blood-2024-207289

Published: 2024

Journal Articles

Safety and Efficacy of Luspatercept for the Treatment of Refractory Anemia in Patients with Myelofibrosis

Ziyu Wen, Xuan Zhou, Bingyu Lin, Xiaoli Liu, Qiang Wang, Na Xu

Blood (2024) 144 (Supplement 1): 6639.

https://doi.org/10.1182/blood-2024-205673

Published: 2024

Journal Articles

BEAT Chemofree Regimen for Relapsed/Refractory and De Novo T-ALL

Jieping Lin, Xuan Zhou, Zhixiang Wang, Dainan Lin, Yu Zhan, Zan Li, Jiwei Huang, Yonghua Li, Xudong Ma, Qifa Liu, Li Xuan, Yang Xu, Hongsheng Zhou

Blood (2024) 144 (Supplement 1): 5901.

https://doi.org/10.1182/blood-2024-203250

Published: 2024

Journal Articles

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults

Sanfang Tu, Lijuan Zhou, Rui Huang, Xuan Zhou, Jilong Yang, Meifang Li, Bo Jin, Langqi Wang, Yaqi Zhuo, Huifang Chen, Lung-Ji Chang, Yuhua Li

Blood (2023) 142 (Supplement 1): 6884.

https://doi.org/10.1182/blood-2023-186622

Published: 2023

Journal Articles

Safety and Efficacy of Single Cycle Blinatumomab Plus VP Chemotherapy for High Tumor Burden Acute Lymphoblastic Leukemia in Adults

Sanfang Tu, Kecheng Wang, Chaoyang Song, Xuan Zhou, Dan Xiong, Guinian Huang, Jia Feng, Jilong Yang, Bo Jin, Bo Wang, Langqi Wang, Yaqi Zhuo, Huifang Chen, Yuhua Li

Blood (2023) 142 (Supplement 1): 5818.

https://doi.org/10.1182/blood-2023-184746

Published: 2023

Journal Articles

Analysis the Relationship between Clonal Hematopoiesis and Cardiovascular Events in Chronic Myeloid Leukemia Based on Next-Generation Sequencing Technology

Jie Luo, Ziyu Wen, Mengxia Zhao, Zicheng Gao, Hong Chen, Qiang Wang, Xuan Zhou, Zherou He, Hanyin Liang, Dongmei Luo, Xiaoli Liu, Qifa Liu, Na Xu

Blood (2023) 142 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2023-182007

Published: 2023

Journal Articles

Bellwave-010: Phase 3, Open-Label, Randomized Study of Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least One Prior Therapy

David Lavie, Muhit Ozcan, Arvind Chaudhry, Xuan Zhou, Ima Paydar, Mohammed Z.H. Farooqui, Paolo Ghia

Blood (2023) 142 (Supplement 1): 3287.

https://doi.org/10.1182/blood-2023-180920

Published: 2023

Journal Articles

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy with Dual Targeting of CD19 and CD70 to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Sanfang Tu, Lijuan Zhou, Rui Huang, Xuan Zhou, Jilong Yang, Meifang Li, Bo Jin, Langqi Wang, Yaqi Zhuo, Huifang Chen, Lung-Ji Chang, Yuhua Li

Blood (2023) 142 (Supplement 1): 3492.

https://doi.org/10.1182/blood-2023-186888

Published: 2023

Journal Articles

Dendritic Cell Vaccines Extend CD19 CAR-T Cell Persistence and Improve the Outcomes in Refractory/Relapsed Adult B-ALL

Sanfang Tu, Lijuan Zhou, Rui Huang, Yanjie He, Xuan Zhou, Jilong Yang, Yuxing Hu, Honghao Zhang, Lung-Ji Chang, Yuhua Li

Blood (2023) 142 (Supplement 1): 3488.

https://doi.org/10.1182/blood-2023-186308

Published: 2023

Journal Articles

Venetoclax Plus Azacitadine for Middle Aged and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial

Blood (2023) 142 (Supplement 1): 4263.

https://doi.org/10.1182/blood-2023-177568

Published: 2023

Journal Articles

Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Trial

Chuting Yang, Yaling Zheng, Chaoyang Song, Ming Wu, Lei Wang, Xuan Zhou, Chunyan Yue, Xiaonan Lin, Jie Chen, Hui Zeng, Rui Huang, Yuhua Li

Blood (2023) 142 (Supplement 1): 7045.

https://doi.org/10.1182/blood-2023-174879

Published: 2023

Journal Articles

Olverembatinib(HQP1351)-Based Therapy in Adults with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Advanced Chronic Myeloid Leukemia: Results of the Real-Life Study

Ziyu Wen, Zhiping Fan, Qiang Wang, Xuan Zhou, Zherou He, Zicheng Gao, Hong Chen, Hanyin Liang, Dongmei Luo, Xiaoli Liu, Hongsheng Zhou, Qifa Liu, Na Xu

Blood (2023) 142 (Supplement 1): 4538.

https://doi.org/10.1182/blood-2023-181850

Published: 2023

Journal Articles

Ruxolitinib or Interferon-α Treatment As a Protective Strategy for Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN) during the COVID-19 Pandemic

Zicheng Gao, Zherou He, Xuan Zhou, Ziyu Wen, Hong Chen, Qiang Wang, Hanyin Liang, Dongmei Luo, Xiaoli Liu, Qifa Liu, Na Xu

Blood (2023) 142 (Supplement 1): 6411.

https://doi.org/10.1182/blood-2023-184700

Published: 2023

Journal Articles

Flumatinib for the Treatment of Adult Patients with Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia: Results from Real-World Data

Xuan Zhou, Na Xu, Ziyu Wen, Hanyin Liang, Dongmei Luo, Hong Chen, Zherou He, Zicheng Gao, Qiang Wang, Dan Xu, Xiaoli Liu, Qifa Liu

Blood (2023) 142 (Supplement 1): 6379.

https://doi.org/10.1182/blood-2023-184643

Published: 2023

Journal Articles

TKI Dose Optimization Based on Therapeutic Drug Monitoring（TDM) with Encouraging Outcomes and Well-Tolerated for Chronic Myeloid Leukaemia Patients

Zherou He, Xuan Zhou, Ziyu Wen, Zicheng Gao, Hong Chen, Qiang Wang, Hanyin Liang, Dongmei Luo, Xiaoli Liu, Na Xu, Qifa Liu

Blood (2023) 142 (Supplement 1): 1807.

https://doi.org/10.1182/blood-2023-182765

Published: 2023

NARROW

Updated Results from a Phase Ⅱ Clinical Trial：Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia

Demographic and Clinical Data in 118 Acquired Hemophilia a: Results from a Single Center Study

Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

Analysis of the Impact of TKI Dose Adjustment Under the Guidance of Blood Concentration Monitoring on the Efficacy, Safety and Quality of Life in Patients with CML

The Efficacy and Safety of Selinexor Plus Ruxolitinib Regimen in Ruxolitinib-Resistant Myelofibrosis: A Retrospective Study

Clinical Characteristics and Risk Factors of Chronic Kidney Disease Among Patients with Myeloproliferative Neoplasms

Safety and Efficacy of Luspatercept for the Treatment of Refractory Anemia in Patients with Myelofibrosis

BEAT Chemofree Regimen for Relapsed/Refractory and De Novo T-ALL

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults

Safety and Efficacy of Single Cycle Blinatumomab Plus VP Chemotherapy for High Tumor Burden Acute Lymphoblastic Leukemia in Adults

Analysis the Relationship between Clonal Hematopoiesis and Cardiovascular Events in Chronic Myeloid Leukemia Based on Next-Generation Sequencing Technology

Bellwave-010: Phase 3, Open-Label, Randomized Study of Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least One Prior Therapy

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy with Dual Targeting of CD19 and CD70 to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Dendritic Cell Vaccines Extend CD19 CAR-T Cell Persistence and Improve the Outcomes in Refractory/Relapsed Adult B-ALL

Venetoclax Plus Azacitadine for Middle Aged and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial

Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Trial

Olverembatinib(HQP1351)-Based Therapy in Adults with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Advanced Chronic Myeloid Leukemia: Results of the Real-Life Study

Ruxolitinib or Interferon-α Treatment As a Protective Strategy for Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN) during the COVID-19 Pandemic

Flumatinib for the Treatment of Adult Patients with Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia: Results from Real-World Data

TKI Dose Optimization Based on Therapeutic Drug Monitoring（TDM) with Encouraging Outcomes and Well-Tolerated for Chronic Myeloid Leukaemia Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only